EMERYVILLE, Calif .– (COMMERCIAL THREAD) – Nanomix Corporation (OTC: NNMX) (“Nanomix” or the “Company”), a leader in the development of mobile, affordable and point-of-service diagnostics, today announced the registration confirmation of the UK Medicines and Health Products Regulatory Agency (MHRA) for the Nanomix eLab system and the S1 panel cartridge.
The Nanomix eLab Analyzer with S1 Panel Cartridge provides several host response biomarker results that can help healthcare providers diagnose and treat patients with critical infections, including sepsis.
“This registration is an important step in accelerating the introduction and availability of Nanomix products to markets and patients across the UK. The S1 panel provides multiple test results from a single patient sample and a single cartridge in under 11 minutes. Timely, bedside diagnostics are targeted to improve treatment and transition of care decisions in healthcare and hospital settings, ”commented John Hardesky, Commercial Director of Nanomix.
About the Nanomix eLab system
The Nanomix eLab is a portable immunoassay and portable chemical diagnostic system. The Nanomix eLab offers the advantages of results in minutes, low cost and portability while providing precise quantitative results comparable in quality to those provided by central laboratory tests.
About the Nanomix eLab S1 Panel Cartridge
The Nanomix eLab S1 panel cartridge is a fully contained, disposable cartridge technology containing reagents and biosensors that provide quantitative measurement of two biomarkers, C-reactive protein (CRP) and procalcitonin (PCT) and lactate metabolite (LAC) , each of which can be used in the assessment of critical infections. The product provides sample-response results that can be used by healthcare providers to aid decision making on antibiotic therapy for patients with suspected or confirmed sepsis and / or suspected or lower respiratory tract infections. confirmed (LRTI) defined as community acquired pneumonia (CAP) acute bronchitis and acute exacerbation of chronic obstructive pulmonary disease (EAMPOC) in a hospital or emergency department.
The Nanomix eLab S1 panel cartridge has received CE mark and MHRA registration.
About Nanomix Corporation
Nanomix is the leader in the development of mobile point-of-care diagnostics with its Nanomix eLab platform and assays that provide rapid, accurate quantitative information for use in contexts where time is of the essence for clinical decision-making and testing. improved patient care. The company’s products are designed to have a broad impact on healthcare delivery by bringing diagnostics to the point of initial patient interaction, whether in hospital or in prehospital care settings, remotely. or alternative, with the aim of enabling faster clinical decision making and potentially treatment in place. Nanomix’s first test addresses the critical need for faster diagnosis of critical infections. The company is developing a pipeline of other tests designed to improve patient outcomes by delivering high-quality diagnostic information within minutes. For more information, visit www.nano.com.
Certain statements contained in this press release constitute “forward-looking statements” within the meaning of federal securities laws. Forward-looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analysis or current expectations regarding, among other things, the current and planned product development of the Company; the Company’s intellectual property position; the Company’s ability to develop business functions; product launch expectations and revenue; the results of operations, cash requirements, expenses, financial condition, liquidity, prospects, growth and strategies of the Company; the industry in which the Company operates; and trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by such forward-looking statements due to various important factors, as well as the risks described in more detail in the section entitled “Risk Factors” in the company’s annual report on Form 10-K for the year ended December 31, 2020, as well as discussions of potential risks, uncertainties and other important factors in the company’s subsequent filings with Securities and Exchange Commission. All such statements speak only as of the date of their publication, and the Company does not undertake to publicly update or revise forward-looking statements, whether as a result of new information, future events or other.
Nanomix eLab is a registered trademark.